about
Primary care of the renal transplant patient.Clopidogrel efficacy and cigarette smoking status.Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?Nocturia and aging: diagnosis and treatment.Blood purification in toxicology: nephrology's ugly duckling.Kidney function assessment and its role in drug development, review and utilization.On warfarin use in kidney disease: a therapeutic window of opportunity?A new forum for brief research reports in AJKD.Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry.[Drug pharmacokinetics in renal failure: What's new?].Gut Colonization with Methanogenic Archaea Lowers Plasma Trimethylamine N-oxide Concentrations in Apolipoprotein e-/- MiceOptimizing drug development and use in patients with kidney disease: opportunities, innovations, and challengesPragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is TurningIntroduction to Nephropharmacology for the Clinician: A New CJASN SeriesUse of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug SubstratesMetabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney DiseaseSimultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of 14CO2 Production Rate DataEngaging and Empowering Stakeholders to Advance PharmacogenomicsAssessing the effect of extracorporeal treatments for lithium poisoningRestoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease
P50
Q33898744-935B35D8-39F8-47CA-9C45-7E631562AF8DQ34640383-2F7166D8-3622-4DB7-99AE-E3C4C7F10396Q37035903-14347DA8-47BF-437F-995B-F097C793A88AQ37770797-EE10BA38-D9D0-49B6-91EB-555D37FCBB24Q37870526-84336841-4A3B-4B42-B4A4-9A3F492D7EA2Q38215907-31D40B07-1F26-4074-90A2-28E4D054EFAAQ42849853-276CF18F-99FB-43A8-B7F8-DA9194976817Q43055475-4A3AB05F-4F91-4AFB-BC00-89984A325E70Q44228277-35034177-E8E7-436F-A5B4-01759FF1F2D4Q53550434-A23426DD-F1A4-4331-A0F9-98D7767B4B52Q57041678-EE263FA7-E8CA-4124-9C2C-4D77191D82ECQ83202198-65A789E4-D4EF-4D44-9361-714E5C1F445AQ87941331-0C276D46-993A-403E-8CD5-7144F3883734Q88376194-3E2D1E95-8D89-46E4-A74A-B7C9082EDFC7Q90737007-8F4B4B57-C390-4B5F-BB6B-AEC958D5887FQ91105810-24BFF5DE-99D0-448E-97D3-F5C5F2B95A46Q92533763-9254D633-96BF-4D3E-9FBB-6289AE927CB8Q93042663-9B2CED2C-77F0-489D-931C-1A6CEB02D269Q96163681-4EC8AE3B-7FB0-4E30-9540-6C020CF72E5DQ96591124-65F64E98-C45B-47C4-9F2F-6DF607FCD065
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas D Nolin
@ast
Thomas D Nolin
@en
Thomas D Nolin
@es
Thomas D Nolin
@nl
type
label
Thomas D Nolin
@ast
Thomas D Nolin
@en
Thomas D Nolin
@es
Thomas D Nolin
@nl
prefLabel
Thomas D Nolin
@ast
Thomas D Nolin
@en
Thomas D Nolin
@es
Thomas D Nolin
@nl
P106
P1153
6602519054
P31
P496
0000-0003-4339-1382